Evaluation of the Therapeutic Effects of a Combination Drug Containing Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Coexisting Hypertension and Dyslipidemia
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0008610
- Lead Sponsor
- Pusan National University Yangsan Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 550
1.Patient diagnosed with essential hypertension and primary hypercholesterolemia, scheduled for treatment with a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe.
2.Patient diagnosed with essential hypertension or primary hypercholesterolemia, currently receiving treatment with antihypertensive or lipid-lowering medications, planning to switch to a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe.
1.According to the approval indications, the combination medication containing losartan and amlodipine should not be administered in cases where there are contraindications specified.
2.The statin class medications (such as rosuvastatin, atorvastatin) and ezetimibe should not be administered in cases where there are contraindications specified.
3.Patients with suspected secondary hyperlipidemia or secondary hyperlipidemia, such as nephrotic syndrome, proteinuria, obstructive liver disease, Cushing's syndrome, etc.
4.If the patient has received investigational drugs for clinical trials within 4 weeks prior to the registration date, or plans to participate in other clinical trials during the study period.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients whose blood pressure (Systolic Blood Pressure, SiSBP; Diastolic Blood Pressure, SiDBP) is controlled according to the target blood pressure guidelines of the '2018 Hypertension Treatment Guidelines' at 12 weeks
- Secondary Outcome Measures
Name Time Method The scores (or change in scores) of the Medication Satisfaction Questionnaire (MSQ), as assessed by patients at the 12-week time point.